JPMorgan Chase & Co. Purchases 226,852 Shares of iShares Biotechnology ETF $IBB

JPMorgan Chase & Co. grew its position in iShares Biotechnology ETF (NASDAQ:IBB) by 27.2% during the third quarter, Holdings Channel reports. The institutional investor owned 1,060,048 shares of the financial services provider’s stock after acquiring an additional 226,852 shares during the quarter. JPMorgan Chase & Co.’s holdings in iShares Biotechnology ETF were worth $153,039,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC boosted its stake in iShares Biotechnology ETF by 96.3% in the third quarter. SG Americas Securities LLC now owns 28,569 shares of the financial services provider’s stock valued at $4,125,000 after acquiring an additional 14,016 shares in the last quarter. Florin Court Capital LLP acquired a new position in shares of iShares Biotechnology ETF during the third quarter worth $11,116,000. Viewpoint Capital Management LLC lifted its holdings in shares of iShares Biotechnology ETF by 1,532.1% during the 3rd quarter. Viewpoint Capital Management LLC now owns 12,730 shares of the financial services provider’s stock valued at $1,838,000 after purchasing an additional 11,950 shares during the last quarter. Bronte Capital Management Pty Ltd. boosted its position in shares of iShares Biotechnology ETF by 12.6% in the 2nd quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock worth $37,000 after purchasing an additional 32,947 shares in the last quarter. Finally, Employees Retirement System of Texas acquired a new stake in shares of iShares Biotechnology ETF in the 2nd quarter worth $25,049,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.4%

Shares of NASDAQ:IBB opened at $174.39 on Friday. The business’s 50-day moving average is $172.18 and its 200 day moving average is $158.82. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $179.64.

iShares Biotechnology ETF Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 19th. Investors of record on Tuesday, December 16th were given a $0.1831 dividend. This represents a $0.73 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, December 16th. This is an increase from iShares Biotechnology ETF’s previous quarterly dividend of $0.08.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.